Long Xiong-En, Xing Hailiang, He Yixin, Meng Xuanli, Ma Yanling, Liu Chang, Cao Xi, Nan Huiru, Cheng Min-Jing, Yan Jia-Lei, Liu Junyang
School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China.
Center for Bioactive Natural Molecules and Innovative Drugs, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
BMC Chem. 2025 Jul 16;19(1):213. doi: 10.1186/s13065-025-01581-4.
Analogues of chlamydocin derivatives consistently demonstrate multifaceted bioactivities, particularly through HDAC inhibition mechanisms, oncolytic efficacy, and neuronal preservation capacities. These activities primarily originate from their unique cyclic tetrapeptide scaffold and functional groups within the side chains that enable specific interactions with biomacromolecules. We herein report the total syntheses of three naturally occurring chlamydocin analogues-koshidacin B, TAN-1746, and Ac-TAN-1746. The synthetic strategy employed a modular approach that involved modifying a common intermediate via late-stage olefin cross-metathesis to install the requisite side-chain fragments. This versatile approach enabled an efficient and divergent total synthesis of the target compounds, completing the syntheses in a longest linear sequence of 9-10 steps. Remarkably, TAN-1746 and Ac-TAN-1746 demonstrated significant anti-osteosarcoma activity that exceeded the potency of clinically employed cisplatin-an observation not previously documented. These results strongly validate the utility of the chlamydocin scaffold as a platform for the development of potent inhibitors with promising therapeutic potential.
衣原体素衍生物类似物始终表现出多方面的生物活性,特别是通过组蛋白去乙酰化酶(HDAC)抑制机制、溶瘤功效和神经保护能力。这些活性主要源于其独特的环状四肽骨架以及侧链中的官能团,这些官能团能够与生物大分子进行特定相互作用。我们在此报告了三种天然存在的衣原体素类似物——小田菌素B、TAN - 1746和Ac - TAN - 1746的全合成。合成策略采用了模块化方法,即通过后期烯烃交叉复分解反应修饰一个共同中间体,以安装所需的侧链片段。这种通用方法实现了目标化合物的高效且多样化的全合成,最长线性序列9 - 10步完成合成。值得注意的是,TAN - 1746和Ac - TAN - 1746表现出显著的抗骨肉瘤活性,超过了临床使用的顺铂的效力——这一观察结果此前未见报道。这些结果有力地证实了衣原体素骨架作为开发具有潜在治疗潜力的强效抑制剂平台的实用性。